News

Characterised by recurrent inflammation of the skin associated with intense pruritus, AD is a non-contagious chronic, inflammatory disease of the skin. Almirall has submitted the application based on

Under the collaboration, AmbioPharm will help Ariceum in manufacturing and supplying cGMP peptide conjugates. The peptide conjugates will be radio-labelled as the radiopharmaceutical end-product and will be used

The financial details of the agreement are not disclosed by the companies. Under the deal, CSL will acquire exclusive and global license to TS23, an enhanced first-in-class anti-α2-antiplasmin

Led by Canaan Ventures, the financing round has seen participation from Taiho Ventures, Osage University Partners, and Sanofi Ventures. Normunity intends to use the funds for advancing its

The regulator has accepted the company’ new drug application (NDA) for the combination therapy and as continuation of quizartinib monotherapy after consolidation to treat FLT3-ITD­–positive AML patients. Quizartinib,

If approved by the regulatory agency, neffy would be the first non-injectable treatment available to patients suffering with allergic reactions of Type I, including anaphylaxis. The regulatory body has

The platform of Refuge is a synthetic biology system leveraging an expression modulation strategy to repress or activate transcription of target genes. Early pre-clinical data indicate a potential

Under the deal terms, Jazz will get exclusive rights to develop and market the antibody across all indications in the US, Japan, Europe, as well as all other

The collaboration will use Charles River’s contract development and manufacturing (CDMO) services to manufacture plasmid DNA and viral vectors for late-stage clinical trials that target degenerative ocular diseases,